Delta-sleep-inducing peptide (DSIP) stimulates the release of immunoreactive Met-enkephalin from rat lower brainstem slices in vitro.
Nakamura. A A; Nakashima. M M; Sakai. K K; Niwa. M M; Nozaki. M M; Shiomi. H H
Key Findings
- DSIP has no direct binding to any opioid receptor subtype.
- At concentrations from 1 pM to 1 nM, DSIP triggers the release of immunoreactive Met‑enkephalin from rat lower brainstem slices.
- The DSIP‑induced Met‑enkephalin release is dependent on calcium, indicating an indirect mechanism.
Practical Outcomes
- For now, the results are purely mechanistic and done in rat brain tissue, so they don’t give a clear dosing or protocol for humans. They suggest DSIP might boost the body’s own opioid system, which could be relevant for pain or sleep, but more human research is needed before biohackers can safely apply this.
Summary
The study shows that delta‑sleep‑inducing peptide (DSIP) doesn’t stick to opioid receptors itself, but at tiny amounts it makes brain tissue from rats release a natural opioid called Met‑enkephalin. This release needs calcium and could explain why DSIP can reduce pain in animals.
Abstract
We studied whether delta-sleep-inducing peptide (DSIP) acted on opioid receptor directly or indirectly. DSIP did not have binding activity to any subtype of opioid receptors. DSIP at doses of 1 pM-1 nM significantly stimulated the release of immunoreactive Met-enkephalin (iME) from superfused slices of the rat lower brainstem. The DSIP-induced release of iME was calcium-dependent. These results show that DSIP acts on opioid receptor indirectly by stimulating the release of iME in producing antinociceptive effects.
Study Information
pubmed
1989
1989-02-27T00:00:00.000Z
10.1016/0006-8993(89)90498-8
19
11